Background: IQ motif-containing GTPase activating 24 protein 3 (IQGAP3), the latest found protein of IQGAP family, 25 may act as a crucial factor in the process of cancer development 26 and progression; however, its clinical value in breast cancer 27 remains unestablished so far. Our team explored the correlation 28 between IQGAP3 expression profile and the clinicopathological 29 features in breast cancer. Methods: IQGAP3 levels in breast 30 cancer cell lines and tumor tissues were detected by real-time 31 PCR and western blotting and compared to the normal control 32 groups. Protein expression of IQGAP3 was evaluated 33 immunohistochemically in specimens (archived paraffin 34 embedded) of 257 breast cancer patients. We also analyze the 35 association between IQGAP3 expression and the clinical 36 characters and prognosis. The relationship between IQGAP3 37 expression and sensitivity to radiation therapy was determined 38 by subgroup analysis. Results: There was significant 39 upregulation of IQGAP3 in breast cancer cell lines and human 40 tumor tissues at both the mRNA and protein level compared to 41 the normal ones. In addition, 110/257 (42.8%) of archived 42 paraffin embedded breast cancer specimens had high protein 43 expression of IQGAP3. High expression of IQGAP3 was 44 significantly related to clinical stage (P=0.001), T category 45 (P=0.002), N category (P=0.001), locoregional 46 recurrence(P=0.002), distant metastasis (P=0.001), and vital 47 status (P=0.001). Univariate and multivariate statistical analysis 48
expression of IQGAP3 of both mRNA and protein level were observed in 114 the all 12 breast cancer cell lines compared with the control cell line of 115 MCF-10A ( Fig.2A) . 116 We used quantitative real-time PCR and Western blotting to evaluate 117 IQGAP3 expression at mRNA and protein levels in tumor samples and 118 the normal control tissues from six different patients. Breast cancer 119 tissues had obviously higher IQGAP3 mRNA and protein levels 120 expression compared with normal breast tissues (Fig.2B) . Therefore, the 121 above results prove IQGAP3 is overexpressed in breast cancer. tumor tissues and normal adjacent tissues(ANT); α-tubulin was used as a loading control. 140 2.2. IQGAP3 overexpression was correlated with the 141 clinicopathological features of breast cancer 142 We investigated the association between IQGAP3 we conduct a multivariate survival analysis in the RT subgroup (n=201):
205
IQGAP3 expression remained an independent prognostic factor for OS 206 and PFS (P = 0.002 and P = 0.001, respectively; (without disease progression).
225
We first analyzed the public microarray TCGA data of breast cancer 226 and found IQGAP3 was overexpressed in radioresistant samples(n=115) 227 compared to radiosensitive samples (n=600; Fig.1B ).
228
To confirm whether IQGAP3 is overexpressed in radioresistant breast 229 cancer patients, we also examined IQGAP3 expression in 159 post-RT 230 patients (radioresistant group n=19; radiosensitive group n=140) using 231 IHC. We demonstrated IQGAP3 was overexpressed in radioresistant 232 breast cancer patients compared to radiosensitive patients (Fig.5 ). analyses showed that IQGAP3 expression, T stage, N stage, ER, and PR 248 were significant prognostic factors for RT outcome (P=0.012, P=0.005, 249 P=0.005, P=0.001 and P=0.001; Table 4 ). IQGAP3 overexpression 250 remaining an independent prognostic factor for shorter RRFS among 251 multivariate analysis (HR: 3.321; 95% CI: 1.135-9.716; P=0.028). [24, 25] . Therefore, we propose a clinical trial of the use of a PI3K 363 inhibitor as a radiosensitizer should be considered for breast cancer 364 patients with high expression of IQGAP3; however, deeper researches are 365 needed to confirm these hypotheses.
252

366
Limitations of our study: first, it was a retrospective study; second, 367 the cohort size was not sufficiently large; and third, some more 368 experiments are need to reveal the precise mechanism of action of 369 IQGAP3 in breast cancer progression and radioresistance. Cambridge, MA). The membranes were stripped and re-probed with an 405 anti-α-tubulin antibody (Sigma, Saint Louis, MI) as a loading control. Louis, MI). The percentage of cancer cells was scored as 1 (<10%), 2 411 (10-50%), 3 (50-75%), or 4 (> 75%); and the staining intensity sorted 412 into four grades: 0 (no staining), 1 (weak staining, light yellow), 413 2(moderate staining, yellow brown), and 3 (strong staining, brown). The 414 scores for the staining intensity and proportion were multiplied. The best 415 cutoff value for IQGAP3 was defined by receiver operating curve(ROC) 416 analysis: a staining score≥6 was classified high expression and score≤4, 417 as low IQGAP3 expression. 
Materials and Methods
Conclusions
430
We are first to report IQGAP3 is overexpressed in breast cancer and 431 its correlation with clinicpathological features. IQGAP3 overexpression 432 was correlated with radioresistance and significantly poorer prognosis.
433
IQGAP3 may be a reliable novel biomarker to provide personalized 434 prognostication and identify patients who may benefit from more 435 aggressive RT treatment for improving the survival of breast cancer patients.
